Autopsy report · NCT01876992

Metformin at the Cellular Level and Dosing for Diabetes Mellitus (DM)

“All investigators/co-investigators relocating to other institutions.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 4 months after it had already started.
• Ran for about 3 years 5 months before it stopped.
• 10 participants enrolled.
• Results were posted on the registry 2 years 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Johns Hopkins University

Sponsor type

University, hospital or other

Conditions

Diabetes; Pre-diabetes; Obesity

Interventions

Metformin

Participants

10

Sites

1

Countries

United States

Trials that died the same way

• Dupilumab Phase 4 Study
  “Investigator moved from institution.” (70% match in meaning)
• Ibuprofen Versus Indomethacin Following Emergent Cerclage Placement
  “Investigative team moved institutions” (66% match in meaning)
• A Study of Oral L-citrulline in Sickle Cell Disease
  “Principal Investigator moved to another institution” (63% match in meaning)
• Impact of Statins on Cytokine Expression in Pneumonia
  “Investigator left institution.” (62% match in meaning)
• Single-portal Endoscopic Carpal Tunnel Release Versus Knifelight for Carpal Tunnel Syndrome. A Randomized Control Trial
  “The principal investigator of the study relocated to another institution.” (61% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.